TSTickerStarGet alerts

EQ 10-Q filed 2026-11-12 | Key takeaways

EQ filed its 10-Q; the most relevant disclosure change is added Subsequent Events - Milestone Financing: On October 26, 2026, the company announced dosing of its first patient in a single ascending dose trial of EQ504 in Australia, constituting the Milestone Event. The company issued 14,957,260 shares of common stock and pre-funded warrants to purchase 20,130,457.

Share this story

Key takeaways

  • Q3 2026 net loss was $4.6 million versus $4.2 million in Q3 2025; nine-month 2026 net loss improved to $14.6 million from $18.6 million in the prior-year period.

  • Phase 1 proof-of-mechanism study of EQ504 was initiated in Australia in October 2026, with topline data anticipated in Q2 2027.

  • The company completed a $20.0 million milestone financing on October 26, 2026, issuing 14,957,260 shares of common stock and pre-funded warrants to purchase 20,130,457 shares.

  • Cash and cash equivalents were $53.3 million as of September 30, 2026, with the company expecting to fund operations into 2029.

  • Research and development expenses increased to $2.5 million in Q3 2026 from $1.3 million in Q3 2025, driven by increased EQ504 development activities.

  • The company plans to initiate a placebo-controlled proof-of-concept study in moderately to severely active ulcerative colitis in H2 2027, subject to supportive Phase 1 data.

Key metrics

Net loss - Q3 2026Q3 2026
$4.6 millionworsened from $4.2 million
Net loss - Nine months 2026Nine months ended September 30, 2026
$14.6 millionimproved from $18.6 million
Cash and cash equivalentsSeptember 30, 2026
$53.3 millionincreased from $33.1 million
RevenueQ3 2026 and nine months 2026
$0No revenue from product sales
Net loss per share - Q3 2026Q3 2026
$0.04improved from $0.06
Net loss per share - Nine months 2026Nine months ended September 30, 2026
$0.14improved from $0.41

Disclosure changes

  • Subsequent Events - Milestone Financing

    On October 26, 2026, the company announced dosing of its first patient in a single ascending dose trial of EQ504 in Australia, constituting the Milestone Event. The company issued 14,957,260 shares of common stock and pre-funded warrants to purchase 20,130,457 shares for approximately $20.0 million in gross proceeds.

    The milestone financing provides additional capital to fund EQ504 development and validates clinical progress.
  • Research and Development Expenses

    R&D expenses were $2.5 million for Q3 2026, driven by increased EQ504 development activities and partially offset by approximately $0.8 million of Australian research and development tax incentive benefits.

    The increase reflects the company's shift in focus to EQ504 clinical development following the wind-down of the EQUATOR study.
  • Clinical Development Pipeline

    Phase 1 proof-of-mechanism study of EQ504 initiated in October 2026 in Australia, evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in approximately 70 healthy subjects with once-daily oral doses ranging from 0.1-3.0 mg.

    The initiation of the Phase 1 study represents a significant milestone in the clinical development of EQ504 for ulcerative colitis.
  • Stockholders' Equity

    Authorized shares of common stock increased from 200,000,000 to 400,000,000 shares on May 28, 2026, following stockholder approval.

    The increase in authorized shares provides flexibility for future equity financings.
  • Liquidity

    Cash and cash equivalents were $53.3 million as of September 30, 2026. The company expects to fund operations into 2029 with current cash and proceeds from the October 2026 milestone financing.

    The improved cash position extends the company's runway and reduces near-term financing risk.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow EQ in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert